Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27899222 | 0.86 | CYP4F2 (0.46) | MTNR1AMTNR1BRIPK1RIPK3CYP4F2 | |
| SCHEMBL5533824 | 0.85 | MTNR1A (0.46) | MTNR1AMTNR1BLMNASMN1; SMN2TSHR | |
| SCHEMBL7517689 | 0.83 | HPGD (0.50) | MTNR1AMTNR1BRIPK1RIPK3CYP4F2 | |
| SCHEMBL21554546 | 0.83 | CA2 (0.50) | MTNR1AMTNR1BLMNATSHR | |
| SCHEMBL1283948 | 0.83 | CA2 (0.50) | MTNR1AMTNR1BRIPK1RIPK3CYP4F2 | |
| SCHEMBL19085086 | 0.83 | MTNR1A (0.47) | MTNR1AMTNR1BRIPK1RIPK3CYP4F2 | |
| SCHEMBL8472346 | 0.83 | MTNR1A (0.42) | MTNR1AMTNR1BRIPK1RIPK3SMN1; SMN2 | |
| SCHEMBL18761597 | 0.82 | CYP4F2 (0.44) | MTNR1AMTNR1BCYP4F2CYP4A11CES2 | |
| SCHEMBL479237 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BRIPK1RIPK3CYP4F2 | |
| SCHEMBL21880654 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BRIPK1RIPK3CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4074701-B1 | NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | LG CHEMICAL LTD (KR) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230101389-A1 | NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-03-30 | — | — | US | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| EP-4074701-A1 | NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | Lg Chem, Ltd. (KR) | 2022-10-19 | — | — | EP | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| CN-114901653-A | Novel amide derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2022-08-12 | — | — | CN | disclosed |
| CN-107428682-B | Amide derivatives, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020187984-A1 | Pharmaceutical uses and synthesis of diketopiperazines | CELLTECH R & D, INC. | 2002-12-12 | — | — | US | disclosed |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | disclosed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064578-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002062797-A2 | PHARMACEUTICAL USES AND SYNTHESIS OF DIKETOPIPERAZINES | CELLTECH R & D, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| US-5508437-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5296608-A | Intermediates for analogs of tyrosine sulfate or tyrosine phosphate containing peptides | HOFFMAN-LA ROCHE INC. (US) | 1994-03-22 | — | — | US | disclosed |
| US-5182263-A | Appetite suppressants | HOFFMANN-LA ROCHE INC. (US) | 1993-01-26 | — | — | US | disclosed |
| EP-0339549-A2 | Tyr-peptide analogs | F. HOFFMANN-LA ROCHE AG (CH) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | MTNR1A 244/4885MTNR1B 252/4885RIPK1 4315/4885 |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | MMP15, MMP13, MMP3 | MTNR1A 308/4885MTNR1B 427/4885RIPK1 4381/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | MTNR1A 1488/4885MTNR1B 916/4885RIPK1 4578/4885 |
| US-20230101389-A1 | NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | DGAT2, DGAT1, MOGAT2 | MTNR1A 3844/4885MTNR1B 2804/4885RIPK1 3386/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | MTNR1A 1488/4885MTNR1B 916/4885RIPK1 4578/4885 |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, DLAT | MTNR1A 4150/4885MTNR1B 3304/4885RIPK1 3947/4885 |
| US-20020187984-A1 | Pharmaceutical uses and synthesis of diketopiperazines | NFKBIA, IKBKE, CHUK | MTNR1A 4046/4885MTNR1B 3153/4885RIPK1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.